news & publications

<< Back to Press Releases

Microchips Biotech, Inc. CEO Cheryl R. Blanchard, Ph.D., Elected to National Academy of Engineering

Election to Academy Is Among the Highest Professional Distinctions Accorded to Engineers

Lexington, Mass – February 5, 2015 – Microchips Biotech, Inc., a developer of implantable drug delivery devices, today announced that its Chief Executive Officer, Cheryl R. Blanchard, Ph.D., was elected as a member of the National Academy of Engineering (NAE), noted to be among the highest professional distinctions accorded to an engineer. Dr. Blanchard was recognized for creation and commercialization of biomaterial products and gender-based medical devices for musculoskeletal health.

“Membership in the NAE is widely considered the most prestigious honor in the engineering profession, and Cheryl’s election is a much-deserved recognition of her established track record as a leader and innovator of medical devices and in the healthcare industry,” said Richard Mott, Executive Chairman of the Board of Microchips Biotech.

Dr. Blanchard is one of 67 newly elected members this year and will be formally inducted into the Academy during the NAE’s annual meeting on Oct. 4th, in Washington, D.C. According to the NAE, the Academy membership honors those who have made outstanding contributions to “engineering research, practice, or education, including, where appropriate, significant contributions to the engineering literature”, and to the “pioneering of new and developing fields of technology, making major advancements in traditional fields of engineering, or developing/implementing innovative approaches to engineering education”.

About Microchips Biotech, Inc.
Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. The company’s proprietary platform technology is a microchip-based implant which can store and release precise doses of drugs at scheduled intervals for up to 16 years. The microchip-based implant has the potential to address significant unmet needs by simplifying dosing regimens and enhancing compliance for patients who need frequent dosing or require regular injections. Microchips Biotech is developing and exploring potential applications for the microchip platform in female contraception, diabetes, osteoporosis and multiple sclerosis. Microchips Biotech was co-founded by renowned MIT researchers Robert Langer, Ph.D. and Michael J. Cima, Ph.D., and is funded by leading healthcare and technology venture investors including Polaris Partners, Medtronic, InterSouth, Flybridge Capital and InterWest.